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Available online 8 January 2015Broad proteomic profiling was performed on serum samples of phase 2 studies (PROVE1,
PROVE2, and PROVE3) of the direct-acting antiviral drug telaprevir in combination with
peg-interferon and ribavirin in subjects with HCV. Using only profiling data from subjects
treated with peg-interferon and ribavirin, a signature composed of pretreatment levels of 13
components was identified that correlated well (R2 = 0.68) with subjects' underlying immune
response asmeasured byweek 4 viral decline and was highly predictive of sustained virologic
response in non-African American subjects (AUC = 0.99). The signature was validated by
predicting in an independent cohort of non-African American subjects treatedwith telaprevir,
peg-interferon and ribavirin (AUC = 0.854). Samples from extreme responders were
over-represented in these analyses. Proteins identified as differentially-expressed between
responders and non-responders to HCV treatment were quantified using multiple reaction
monitoring in samples from all Caucasian subjects in the peg-interferon and ribavirin arms of
PROVE1 and PROVE2, revealing 15 proteins that were significantly differentially expressed
between treatment responders and non-responders. Seven of the proteins are part of focal
adhesions or other macromolecular assemblies that form structural links between integrins
and the actin cytoskeleton and are involved in antiviral response.
Biological significance
HCV is a significant health problem. We describe a novel approach for identifying markers
that predicts HCV treatment response different treatment regimens and use this approach
to identify a novel HCV treatment response signature. The signature has potential to guide
optimization of HCV treatment regimens.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Hepatitis is a chronic inflammatory condition of the liver caused
by hepatitis C virus (HCV) infection. Approximately 170 million
people worldwide are chronically infected with HCV [1]. HCVcals Incorporated, 50
by Elsevier B.V. This
nd/4.0/).infection is one of the leading causes of both liver transplant and
cancer-related death in the United States because it is a major
risk factor for cirrhosis and hepatocellular carcinoma [2,3]. The
goal of HCV treatment is eradication of the virus as determined
by achievement of a sustained virologic response (SVR).
Molecular biomarkers have long been sought to guide
clinical care for subjects infected with the HCV. HCV genotype
was identified more than a decade ago as a strong predictor ofis an open access article under the CC BY-NC-ND license
60 J O U R N A L O F P R O T E O M I C S 1 1 6 ( 2 0 1 5 ) 5 9 – 6 7treatment outcome [4] and is still used to determine the best
treatment regimen for a subject [5]. Circulating markers of
liver damage are indicators of severe fibrosis in HCV subjects
[6] and are used clinically to predict prognosis and to trigger
monitoring for hepatocellular carcinoma [7].
The introduction of broad molecular profiling greatly accel-
erated the discovery of novel predictive biomarkers of response
for HCV. A genome-wide association study found that genetic
polymorphisms near the IL28B gene were a major determinant
of SVR to interferon-based treatments [8]. However, IL28B
genotype explains only about 15% of the variability in response
to treatment, implying the involvement of other factors [9].
Genome-wide expression profiling of liver samples from
HCV-infected subjects identified strong predictors of SVR for PR
treatment [10], but a liver biopsy would be required to use these
biomarkers clinically. A proteomics-based approach employing
liquid chromotagraphy mass spectrometry (LC–MS) identified
pretreatment serum markers of SVR for interferon-based
treatment [11]. The common theme between each of these
elegant works is that the identified biomarkers predict SVR for a
specific interferon-based regimen.
However, standard treatment for HCV infection is rapidly
transitioning away from interferon-based regimens. In order
to improve response rates and shorten treatment duration,
the cornerstone of HCV treatment for many years, pegylated
interferon with ribavirin (PR), has been augmented with
direct-acting antivirals such as the protease inhibitors telaprevir,
boceprevir, and simeprevir. These protease inhibitors specifically
bind to the HCV nonstructural 3/4A serine protease [12]. The
direct-acting antiviral sofosbuvir was recently approved as part
of all-oral or interferon-containing combination regimens [13],
and other all-oral combinations are progressing in the clinic.
Markers for interferon response may predict outcome to HCV
treatment regardless of regimen. Interferon response has been
shown to affect the treatment outcome for both interferon-based
[14,15] and interferon-free regimens [16,17], suggesting that the
variability observed in interferon-based regimens may reflect
underlying variation in subjects' immune response toHCV rather
than interferon-specific variation. Consequently, identifying
predictors of interferon response may have broad utility in
predicting SVR for HCV treatment regimens.
Here, we report the discovery of a novel immune response
signature in HCV using data solely from PR treatment.
The signature accurately predicted SVR for the PR regimen.
Furthermore, we independently validated the signature by
demonstrating that it predicted SVR for PR augmented with
telaprevir (T/PR), thereby providing further evidence that inter-
feron response underlies response to direct-acting antivirals. To
better understand the biology underlying the PR signature,
differentially-expressed components were identified using LC–
MS resulting in the identification of 71 proteins. These proteins
were quantified in a broad set of subjects with HCV treated with
PR, resulting in the identification of 15 proteins that were
differentially expressed between treatment responders and
non-responders. The differentially-expressed proteins revealed
a host response to HCV infection that was not previously known
to affect treatment outcome. Finally, literature data reportingSVR
rates for various regimens was used to provide quantitative
evidence that the SVR rates for both interferon-based and
interferon-free regimens are correlated in subject populationswith different interferon responses, suggesting that markers
correlating with interferon response are broadly useful for
predicting response to HCV treatment.2. Methods
Methods are described in detail in a Data in Brief article [44].
All subjects from which samples used in this study were
collected were enrolled in The Protease Inhibition for Viral
Evaluation trials (PROVE 1, 2 and 3) [14,18,19]. The PROVE 1
and 2 trials enrolled treatment naïve subjects and the PROVE 3
trial enrolled subjects who previously failed PR treatment.
Demographic information for all the subjects from which
profiling samples were obtained is in Table 1 in [44]. The
protocol conformed to the ethical guidelines of the 1975
Declaration of Helsinki, and was approved by the institutional
review board at each participating site. All patients provided
written informed consent.
2.1. Broad proteomic profiling (discovery stage)
2.1.1. Sample selection and mass spectrometric analysis
Pre-treatment serum samples were analyzed for 50 subjects in
the PR arms of the PROVE 1 and PROVE 2 trials. Among the 50
subjects, 25 subjects achieved SVR and 25 failed to achieve
SVR in the clinical trial. Samples from subjects with the best
response to PR (undetectable virus or lowest viral titer at week
4) were selected for profiling in the discovery stage. The
samples from the 25 non-responder subjects were chosen to
match demographic characteristics of the 25 responders. Only
samples from non-responders who were adherent to treat-
ment, defined as completing dosing, or stopping treatment
based on pre-defined stopping rules for virologic failure, were
selected for profiling.
The remaining samples were from subjects in the T/PR arms
of the PROVE 1, PROVE 2 and PROVE 3 trials. T/PR treatment
non-responders were defined as subjects who completed at least
four weeks of T/PR dosing and failed to achieve undetectable
virus at any time-point during the study. Samples from a total of
38 Caucasian treatment non-responders were profiled in the
discovery stage. Additionally, samples from 49 Caucasian sub-
jects who achieved SVR in the study were chosen to match
demographic characteristics of the T/PR non-responders. Finally,
all 35 pretreatment samples from African Americans enrolled in
T/PR arms of the PROVE 1, PROVE 2 and PROVE 3 studies were
profiled in the discovery stage. Seven sampleswere omitted from
the statistical analysis because they appeared to contain very
high abundance of proteins thatwerenot completely removed by
the immunoaffinity depletion. Demographics for the subjects
used in statistical analyses are summarized in Table 1 in [44].
Samples were depleted of abundant proteins, digested
with trypsin and analyzed by liquid chromatography/mass
spectrometry (LC–MS). Detected ions were matched across
samples and compared for relative peak intensity.
2.1.2. Predictive model
The decline in viral titer at week 4, rather than SVR, was used
as a continuous metric to quantify interferon response in the
predictive model. By using a continuous metric for interferon
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lating with SVR can be used for different regimens.
An elastic-net regularized linear regression model was
implemented in R 3.0.1 (R Core Team 2013. R: A language and
environment for statistical computing. R Foundation for
Statistical Computing, Vienna, Austria. URL http://www.R-
project.org/) to predict change-from-baseline viral titer at
week 4 (using log 10 transformed viral titers). ROC curves
and AUCs were also calculated using R.
2.1.3. Identification of differentially-expressed components
Differentially-expressed components were targeted for se-
quencing by liquid chromatography–tandem mass spectrome-
try (LC–MS/MS). Peak intensitieswere normalized to account for
small differences in protein concentration between samples
and a multifactor ANOVA analysis was then applied to identify
components that were differentially expressed between the
groups of interest. Samples were then reanalyzed by LC–MS/MS
to identify components that were found to be significantly
differentially expressed. In addition to the components
that were differentially expressed between responders and
non-responders to PR and T/PR treatment, significant compo-
nents from the statistical comparisons listed inTables 2 and6 in
[44] were targeted for sequencing. Peptide sequences obtained
were clustered by homology into their parent proteins.
2.2. Multiple reaction monitoring (MRM)
2.2.1. Sample selection and analysis
All available pretreatment serum samples from the PR arms of
the PROVE 1 and 2 trials (treatment naïve) were profiled using
MRM assays monitoring the differentially-expressed compo-
nents identified in the discovery stage. Samples from a total of
156 subjects were profiled. Demographics for these subjects
were summarized in Table 1 in [44]. Serum samples from 17
healthy (non-HCV infected) subjects were also profiled. The
final analysis set consisted of a total of 139 Caucasian subjects
(126 subjects with HCV infection and 13 healthy controls).
Samples were randomized, depleted of high abundance
proteins, and digested with trypsin. For the MRM analysis, 354
transitions were monitored, corresponding to 176 peptides,
representing 71 proteins that were identified as differentially
expressed in the discovery stage. TheMRMassaywas developed
using 176 synthetic reference peptides corresponding to the
peptides of interest. Peptide transition peak areas were deter-
mined and, after applying detection rate thresholds, 195
transitions representing 54 proteins were included in the
analysis. The data were normalized using the intensity of an
internal standard peptide to account for instrument variability.
The transitions of each protein were then combined to create
protein-level intensity values using eigendecomposition of the
covariance matrix. The Wilcoxon rank sum test was used to
assess statistical significance of differences in protein intensities
between groups with correction for multiple testing.3. Results
A total of 381 unique components (peptide ion peaks) were
identified as differentially expressed between subjects thatachieved SVR (responders) or failed to achieve SVR (non-
responders) on PR or T/PR regimens in the discovery stage.
The significant components in the two treatments were
highly overlapping (p < 10−16, see Figure 1 in [44]).
3.1. Identification of a predictor for interferon response
An interferon response signature was identified using data
solely from PR subjects. Specifically, the week 4 change-
from-baseline HCV RNA titer was correlated to the intensity of
components identified by LC–MS (peptide ion peaks) using a
linear model and cross validation to avoid overfitting. The
resulting model, with coefficients shown in Table 2 in [44],
consisted of 13 components and had a high correlation
between predicted and observed week 4 change-from-
baseline viral titers (R2 = 0.68). The model was used to predict
SVR for PR subjects using receiver operating characteristic
(ROC) analysis. As shown in Fig. 1A, the model produced
nearly perfect prediction of PR response with a sensitivity and
specificity of 0.96 and area under the curve (AUC) of 0.99.
As an independent validation, the interferon response
signature was used to predict the SVR rate for a cohort of T/PR
subjects. Since week 4 change-from-baseline HCV RNA titer
following PR treatment alone was not available for subjects
treated with T/PR, these values were first predicted for the
subjects treated with T/PR and then used to predict SVR for
the T/PR regimen using ROC analysis. The model accurately
predicted T/PR response in non-African American subjects
(AUC = 0.854 in Fig. 1B). The model was tested only on
non-African American subjects treated with T/PR because
significant differences in component levels were found
between African American and Caucasian subjects (see Tables
3 and 4 in [44]) and the PR dataset used to build the model did
not contain any African Americans.
Differentially-expressed components observed in the dis-
covery stage were targeted for sequencing and a total of 71
proteins were identified (see Table 5 in [44]). Five of the 13
components in the model predicting response to PR and T/PR
were identified by LC–MS/MS sequencing (see Table 2 in [44]).
Two of the identified transitions in themodel corresponded to
peptides derived from LGALS3BP and one to a peptide derived
from CNDP1. In addition, two of the components in the model
were peptidoglycans composed of different N-linked glycans
attached to a peptide derived from LGALS3BP. The two
glycans had an identical core structure and differed by the
number of terminal sialic acid moieties (see Table 2 in [44]).
The unidentified peaks in the model may represent
non-proteomic components of the serum, such as metabo-
lites. However, the identified components already captured
much of the variability in treatment response, since a model
built using only the five identified components and fitted
using only subjects treated with PR predicted SVR for the PR
(AUC = 0.97) and T/PR regimens (AUC = 0.81) reasonably well
(see Table 6 and Fig. 2 in [44]).
3.2. Biological mechanism underlying the signature
In a subsequent stage, proteins identified in the discovery
stage as differentially-expressed between responders and
non-responders to HCV treatment were quantified using
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Fig. 1 – ROC curves predicting SVR for (A) PR subjects, (B) an independent cohort of subjects treated with T/PR using the same
model as in A.
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1 and PROVE 2. Among Caucasian subjects, fifteen proteins
were significantly differentially expressed between re-
sponders and non-responders to PR (Table 1 and Fig. 2). As
shown in Table 2, both the magnitudes and statistical
significance of differences in the protein levels between
responders and non-responders were the largest in the
subgroup of subjects with the least advanced fibrosis. The
heatmap in Fig. 2 also shows high intensities (red) for many of
the proteins in responder subjects with low fibrosis scores
(subjects on the far left of Fig. 2).
The source of the serum protein response signature
appears to be the liver. All of the proteins in the response
signature were reported to be expressed in human liver in the
Human Liver Proteome project [20]. Additionally, all of the
proteins except FERMT3 were reported in the literature to be
expressed in the liver (see Table 7 in [44]).
A subset of the differentially-expressed proteins was highly
correlated with one another (Fig. 3A, see also Table 7 in [44]).
Pairwise Pearson correlation coefficients among ZYX, TAGLN2,Table 1 – Significant proteins from MRM analysis.
Protein Responder vs.
non-responder
R
fdr DI f
TLN1 0.03 2.3 0
FERMT3 0.02 2.1 0
CNDP1 0.009 2.0 0
TAGLN2 0.02 2.1 0
ZYX 0.02 2.1 0
CLIC1 0.03 1.9 0
PARVA/B 0.02 1.3 0
PFN1 0.02 2.2 0
AZGP1 0.03 1.5 0
GSTP1 0.03 1.5 0
VCL 0.02 1.8 0
ORM1 0.02 1.4 0
C9 0.02 1.3 0
APOA4 0.04 1.2 0
LGALS3BP 0.02 0.57 0
fdr: false discovery rate.
DI: median differential intensity.PFN1, FERMT3, PARVA/B, GSTP1, VCL and TLN1 ranged from 0.63
to 0.91. Among the rest of the differentially-expressed proteins,
only two pairs (AZGP1/APOA4 and AZGP1/C9) had correlation
coefficients above 0.5. The levels of the differentially-expressed
proteinswere not strongly correlatedwith the clinical covariates
age, BMI, baseline HCV RNA or alanine aminotransferase level
(see Table 8 in [44]).
3.3. SVR rates in subject populations with different interferon
responses were correlated in many interferon-based and
interferon-free regimens
SVR data were tabulated from clinical trials of interferon-
based and interferon-free regimens two subject populations
with distinct interferon responses populations (see Fig. 4, see
also Table 9 in [44]). The two subject populations were
treatment naïve and prior null responders. Treatment naïve
subjects have not previously been treated and therefore this
subject population contains the full spectrum of interferon
responses. Prior null responders experienced a poor virologicesponder vs. healthy Non-responder
vs. healthy
dr DI fdr DI
.07 2.0 0.3 1.2
.07 3.4 0.6 1.6
.9 0.99 0.02 0.47
.07 2.8 0.8 1.3
.07 5.7 0.3 2.8
.07 1.1 0.2 0.59
.07 1.3 0.3 1.0
.07 2.8 0.6 1.4
.7 0.81 0.03 0.55
.08 3.1 0.4 1.8
.07 2.7 0.3 1.5
.8 0.81 0.2 0.60
.3 0.77 0.02 0.60
.7 1.1 0.5 0.83
.07 1.7 0.007 2.9
A B
1-specificity
0 0.2 0.4 0.6 0.8 1.0
se
n
si
tiv
ity
0
0.2
0.4
0.6
0.8
1.0
response
fibrosis
+ -
APOA4
AZGP1
C9
CNDP1
CLIC1
FERMT3
GSTP1
LGALS3BP1
ORM1
PARVA/B
PFN1
TAGLN2
TLN1
VCL
ZYX
Fig. 2 – Heat map of all protein intensities from the MRM assays. The colored bar above the heat map shows fibrosis stage for
each subject (dark red = no orminimal fibrosis, medium red = portal fibrosis, bright red = bridging fibrosis). Treatment response
is denoted by + (responder) and − (non-responder). Proteins that are significantly differentially expressed between responders
and non-responders are labeled on the heat map. Maximum andminimum intensity values are set to 4 log (base 2) units from
the median intensity for each protein.
63J O U R N A L O F P R O T E O M I C S 1 1 6 ( 2 0 1 5 ) 5 9 – 6 7response to treatment with interferon (less than 2 log 10 unit
decline in viral titer at week 12) and therefore are the most
difficult-to-treat subjects. The data were from (1) interferon-
based regimens combined with protease inhibitors (telaprevir,
simeprevir, and faldaprevir), (2) interferon-free regimens
containing the nucleotide inhibitor sofosbuvir, and (3)
interferon-free regimens containing the protease inhibitor
ABT-450. As seen in Fig. 4, a clear correlation was observed
in the SVR rates of the two subject population across all of
these regimens, even those regimens that did not contain
interferon.Table 2 –Median differential intensities, responders vs.
non-responders, stratified by fibrosis stage for proteins
from MRM analysis.
Protein Fibrosis stage
No or minimal (39) Portal (68) Bridging (19)
TLN1 4.7* 1.0 1.7
FERMT3 5.2* 1.2 3.6
CNDP1 1.5 2.9 1.1
TAGLN2 4.9 1.5 2.3
ZYX 3.6 1.8 2.5
CLIC1 2.2 1.2 2.5
PARVA/B 1.6* 1.2 1.5
PFN1 5.0* 1.7 2.8
AZGP1 2.0 1.4 0.55
GSTP1 4.0* 1.1 0.60
VCL 3.7* 1.5 2.3
ORM1 2.2 1.5 0.85
C9 1.2 1.4 1.1
APOA4 1.9 1.1 1.1
LGALS3BP 0.78 0.43 0.68
fdr * <0.1.
Numbers in parentheses following fibrosis stage are numbers of
subjects in each fibrosis stage subgroup.4. Discussion
4.1. Predicting HCV treatment outcome
We used broad serum proteomic profiling to identify a novel
interferon response signature in HCV using data solely from a
PR regimen. Rather than identify a signature to predict SVR
directly, we identified a signature correlating baseline serum
protein with the week 4 viral decline during PR treatment.
Using ROC analysis (Fig. 1), the PR response signature
accurately predicted SVR for the PR regimen (AUC = 0.99). As
an independent validation, the signature also accurately
predicted SVR for a cohort of T/PR subjects not included in
the model fitting (AUC = 0.854).
The decline in viral titer at week 4 during PR treatment has
previously been used as the basis for response-guided therapy
to treatmentwith boceprevir combinedwith PR [15]. Correlating
the proteinmarkers to this decline in viral titer had twoprimary
benefits: (1) using continuous as opposed to binary measures
such as SVR increased the statistical power to identify a
regressionmodel [21], and (2) predicting a continuous response
allowed for flexibility to assign different SVR cutoffs to different
regimens. Flexibility in assigning the SVR cutoff was critical for
using the signature to predict both PR and T/PR responses since
T/PR had a higher SVR rate than PR (see Table 1 in [44]).
The ability to accurately predict T/PR treatment outcome
using a signature identified using only subjects treated with
PR is consistent with the results of the literature analysis
(Fig. 4) showing that SVR rates in two subject populations with
different interferon responses were correlated across both
interferon and interferon-free regimens.
These results are also consistent with two previous clinical
observations. First, individual subjects' interferon response
correlated with outcome even for interferon-free regimens
[16,17]. Second, a given subject population can be characterized
as having an expected distribution of interferon responses [22].
Fig. 3 – (A) Heat map showing Pearson correlation coefficients between all the pairs of significantly differentially-expressed
proteins using data from the MRM analysis. (B) Interaction network based on KEGG human focal adhesion pathway [42].
Additional proteins were added based on references in the text. Squares and circles represent HCV and human proteins,
respectively. Red circles are proteins that are expressed at significantly higher levels in PR responders than non-responders.
Lines represent published protein–protein interactions referenced in the text and curated by Entrez Gene [43].
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broad predictor of SVR for all HCV regimens. Furthermore, as
shown in Fig. 5, using a predictor of interferon response – such
as the one described here – and then assigning a regimen-
specific cutoff at which SVR is achieved may be a viable path
toward building a treatment outcome predictor for any HCV
regimen.
A limitation of the signature reported here is that it was
identified and validated using PR and T/PR subject popula-
tions enriched for extreme responders, and thus the accuracy
of SVR prediction may be lower in more representative
populations. An estimate of the ability of the identified
proteins to predict SVR for PR treatment in a representative
population may be made using the MRM dataset containingFig. 4 – Scatterplot comparing SVR rates from clinical trials of
all-oral HCV regimens. Point estimates and 95% confidence
intervals are shown. The x and y axes are the SVR rates for
PR naïve and PR null responders, respectively. Red dots
denote clinical trials of HCV regimens containing interferon.
Blue dots denote clinical trials of interferon-free regimens.
References for the trials are in Table 9 in [44].all subjects in the PR arms of the PROVE 1 and PROVE 2 trials.
A model built with cross validation using this dataset
had approximately the same accuracy for predicting SVR
(AUC = 0.82) (see Fig. 3 in [44]) as the validated model
published by Patel et al. (AUC = 0.86) [11]. These two data
points suggest that baseline proteomicmarkers can predict PR
response with AUC in the range 0.8–0.9.
4.2. Biological mechanisms underlying the response signature
Fifteen proteins that correlated with PR response were
identified in this study. These proteins are not used in theFig. 5 – Overview of the proposed approach for using
subjects' interferon response to predict response to HCV
treatment. The dashed lines show the different cut-offs
corresponding to SVR for PR (PR SVR), T/PR (T/PR SVR), and a
potent interferon-free regimen (IFN-free SVR). The shaded
area under the curve shows the expected portion of the
population that will achieve SVR when treated with a PR
regimen.
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fied as serum biomarkers for liver fibrosis in HCV subjects [23].
The transitions identified in the discovery model correspond
to peptides or glycopeptides derived from either LGALS3BP or
CNDP1. Among the components in themodel were two distinct
glycopeptides derived from LGALS3BP (see Table 2 in [44]).
LGALS3BP was previously reported to correlate with treatment
outcome [24,25], but the discovery of glycopeptide predictors of
HCV treatment is novel and consistent with alterations of
protein glycosylation patterns in liver disease [26].
The fifteen proteins that were differentially expressed
between responders and non-responders to PR treatment
(Table 1) reveal a host mechanism that was not previously
linked to HCV treatment outcome. Seven of the fifteen
proteins were part of macromolecular complexes that bind
integrins or actin. Immune adhesion mechanisms have been
linked to HCV pathogenesis [27]. But it cannot be excluded
that the relationship found here between adhesion and HCV
treatment outcome is independent of HCV infection.
Direct interactions among the seven differentially-expressed
proteins are shown in Fig. 3B. Four of the seven proteins (TLN1,
PARVA/B, VCL and ZYX) are part of focal adhesions.
Focal adhesions are macromolecular assemblies located at
cell-extracellular matrix contact points that mediate extracel-
lular matrix effects on cell behavior [28]. Specifically, the four
proteins are scaffolding proteins that crosslink the cytoskeletal
protein actin to membrane glycoproteins, such as integrins
(Fig. 3B). Among the other differentially-expressed proteins in
our dataset, FERMT3 is an established integrin adaptor protein
[29], and PFN1 [30] and TAGLN2 [31] both bind actin.
Consistent with the coordination of their biological func-
tion, the seven proteins are part of a tight co-expression
network together with another of the differentially-expressed
proteins, GSTP1 (glutathione-S-transferase) as shown in
Fig. 3A. All eight of these proteins were expressed at higher
levels in HCV-infected relative to healthy subjects (Table 1).
GSTP1 up-regulation in subjects infected with HCV may be a
response to oxidative stress induced by the virus [32], but the
mechanism underlying GSTP1 co-expression with the other
proteins in Fig. 3A is not clear.
Up-regulation of focal adhesion pathways may be a host
response to control HCV infection. Proteins in the focal
adhesion pathway were overrepresented in a genome-wide
HCV-human interactome map generated by yeast two-hybrid
screens [33]. Fig. 3B shows interactions between HCV proteins,
mainly NS3 and NS5A, and components of the integrin/actin
network. Expression of the HCV NS3 or NS5A proteins in HEK
cells reduced integrin-dependent, but not integrin-independent
adhesion [33]. Larger magnitudes and statistical significance of
differences in the protein levels between responders and
non-responders in the subgroup of subjectswith least advanced
compared to more advanced fibrosis (Table 2), imply that
up-regulation of focal adhesion pathways is part of an early
host response to HCV infection.
The role of focal adhesions in retroviral and HCV infection
may be similar. Overexpression of the focal adhesion compo-
nents TLN1 or VCL reduced the susceptibility of human cell
lines to retroviral infection by blocking infection early in the
viral life cycle [34]. Consistent with our HCV findings, VCL,
TLN1 and another focal adhesion component, FLNA, were allexpressed at higher levels in PBMCs of HIV-infected compared
to control subjects [35].
Differential expression inHCV-infected compared to healthy
subjects of four of the differentially-expressed proteins was
consistent with a more advanced disease state in the subjects
infected with HCV. CNDP1, a histidine dipeptidase, was
expressed at lower levels in individuals with more severe
fibrosis [36]. AZGP1 was reported to be a tumor suppressor in
pancreatic cancer [37]. Low expression of AZGP1 predicted
recurrence in prostate cancer [38] and is associated with poor
prognosis in liver cancer [39]. C9 was expressed at lower levels
in liver cancer specimens compared to normal tissue [40].
LGALS3BP levels correlated with extent of fibrosis in HCV
subjects [41]. For each of these proteins, levels in treatment
non-responders compared to responders correlated with more
advanced disease.5. Conclusion
Protein markers of interferon response are promising predic-
tors of outcome to HCV treatment for both PR and the
direct-acting antiviral telaprevir combined with PR. Further-
more, the markers may be broadly useful for predicting
outcome to HCV treatment regardless of treatment regimen.Conflict of Interest
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